Pharma's Almanac’s Post

I am honored to have participated in Pharma's Almanac's recent roundtable, where industry leaders discussed the pivotal regulatory decisions shaping the future of biopharma in 2024 and beyond. In my contribution, I highlighted the emerging regulatory framework for generative AI technologies. As we integrate these technologies into drug development and patient care, it is crucial to establish responsible usage guidelines that minimize bias in AI outputs. Read the full roundtable discussion to gain insights from industry experts on the dynamic regulatory landscape that will drive innovation and ensure safety across the sector. https://lnkd.in/g-yU58uV #Biopharma #AI #Innovation #Regulation

There are more than 300 GLP-1RAs in an active stage of development, from industry giants and potential market disrupters. While mega-cap companies dominate the GLP-1RA market and are expected to maintain their stronghold in 2030, three smaller biotechs – Viking Therapeutics, Inc., Altimmune, Inc., and Structure Therapeutics – are emerging as potential disrupters in this drug category, giving hope to innovative newcomers. Click here for the full article - https://lnkd.in/d8QNQ6z7 #pharma #GLP1 #biotech #biopharma

Introducing analytical methods in drug discovery takes time - learn how scientists from Novartis, Biogen and SCIEX screen and analyze intact proteins in discovery assays in this roundtable. Watch here: https://bit.ly/3Wmy23O #DanaherLifeSciences #Echo #MS #massspec #drugdiscovery

The Final Competition of Epoch IV Though it’s the last, it’s certainly not the least. This competition, hosted by Leash Bio, aims to predict small molecule-protein interactions, a crucial aspect of drug development. Machine learning (ML) models can predict the binding affinity of small molecules to specific protein targets- a critical step in drug development for the pharmaceutical industry that paves the way for more accurate drug discovery. This competition links to goal #3: Good health and well-being. Using machine learning to search for the perfect ligand in the 1060 chemicals in the drug-like space will revolutionize the way medicine is developed and could speed up the process of curing diseases.

We all know the importance of Sample Management. Why not join #Avantor next week at our 4th EU Sample Management Symposium?! See below for more details and the links to register - see you there !! #Pharma #biotech #Avantorsetsscienceinmotion #SLAS2024

Looking forward presenting in 2 weeks, for the first time externally, our work on shipments with clinical samples, their carbon footprint, and how we can reduce (and get savings along!)... The title of that Symposium is "Challenges and Solutions of Sample Management": I believe that a challenge (to come) is how we will operate by 2030 in a context of targeted carbon-neutrality (scopes 1, 2 & 3). I will present there one solution we built, which will help a lot in that direction - among others! #environmental #sustainability #shipments #clinical #samples #Novartis

Thoughts on this? >> Lyell Immunopharma to acquire ImmPACT Bio, cut top programs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #healthcare #productmarketing

Denmark-based Adcendo is the latest biotech to secure funding in the antibody-drug conjugate (ADC) space, raising $135m to advance its portfolio of first-in-class ADCs into the clinic.  Click here for the full article - https://lnkd.in/dsP86sxR #pharma #ADCs #biotech #biopharma

Dive into Pharma's Almanac roundtable for insights from leading experts at companies like Lonza, Samsung Biologics, and Thermo Fisher Scientific. Discover how the pharmaceutical industry is harnessing fresh ideas from adjacent sectors to boost drug development!